1. Mutational Testing to Select Novel Targeted Therapies in AML

3. Key Points From de novo AML Genome Atlas

4. Current Guidelines for Cytogenetic/ Molecular Testing in AML: NCCN

5. Current Guidelines for Cytogenetic/ Molecular Testing in AML: ELN

6. Guidelines for Gene Panel Diagnostics

7. Risk Stratification and Cytogenetic and Molecular Abnormalities in AML

8. AML: General Treatment Principles

9. Treatment of AML in Patients < 60 Years (non-APL)

10. Induction Considerations

11. Quality of Remission Matters

12. Relapsed/Refractory AML

13. Examples of Novel Targeted Therapies in AML

14. Emerging Targeted Therapies

15. Emerging Targeted Therapies (cont)

16. Emerging Targeted Therapies (cont)

17. Emerging Targeted Therapies (cont)

18. Emerging Targeted Therapies (cont)

19. RATIFY Trial

20. IDH Inhibitors

21. BCL-2

22. Venetoclax: BCL-2 Selective Inhibitor

23. Low-Dose Ara-C Plus Venetoclax

24. Phase 1b Study of Venetoclax in Combination With HMA

25. Single-Agent MDM2 Inhibition

26. Other Emerging Therapies

27. Integrating Novel Therapies Into Practice: Suggestions and Predictions

28. Integrating Novel Therapies Into Practice: Suggestions and Predictions (cont)

29. What Should Be on Your Radar?

30. What Should Be on Your Radar? (cont)

31. Abbreviations

32. Abbreviations (cont)